FDA grants orphan drug designation to onvansertib for relapsed or refractory CMML, boosting development of the PLK1 inhibitor after early signals of activity.
Commentary|Videos|December 11, 2025
Dr Fadi Haddad Advises Clinicians on Asciminib Treatment in CML
Author(s)Fadi Haddad, MD
Fact checked by: Paige Britt, Cheney Gazzam Baltz
Fadi Haddad, MD, discusses the use of asciminib in patients with chronic myeloid leukemia.
Advertisement
Watch part 1 of the interview
In the second part of our interview with Fadi Haddad, MD, an assistant professor and coleader of the Section of Chronic Myeloid Leukemia in the Department of Leukemia, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center in Houston, he breaks down the adverse events associated with asciminib (Scemblix) and offers advice to oncologists.
Advertisement
Related to this article
At Rutgers Cancer Institute, neuro-oncologists met to discuss the latest trends in precision brain cancer care with FET-PET imaging, advanced molecular testing, and same-day multidisciplinary clinics.
Multiple oncologists share their perspectives on what is still limiting access to CAR T-cell therapies in 2026.
Breakthrough targeted therapies—from KRAS and PROTACs to CAR T—plus ctDNA monitoring and personalized vaccines push earlier detection and smarter cancer treatment.
J. Thaddeus Beck, MD, discusses how the shift from intravenous to subcutaneous formulations is changing oncology practice, from clinic logistics to patient preferences.
Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.
Cancer deaths keep falling as survival rises, fueled by prevention, early detection, and therapies, yet gaps persist, and research funding uncertainty threatens future gains.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
2
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
3
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
4
Rusfertide Improves Hematocrit Control, Reduces Phlebotomy in Polycythemia Vera
5